skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Mostrar Somente
Refinado por: Base de dados/Biblioteca: Academic OneFile remover tipo de recurso: Anais de Congresso remover Journals@Ovid Complete remover nível superior: Recursos Online remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
POS0065-PARE EDUCATION FOR PATIENTS, DESIGNED BY PATIENTS: THE EXPERIENCE IN THE DESIGN OF A RHEUMATOID ARTHRITIS PRIMER
POS0065-PARE EDUCATION FOR PATIENTS, DESIGNED BY PATIENTS: THE EXPERIENCE IN THE DESIGN OF A RHEUMATOID ARTHRITIS PRIMER
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

POS0065-PARE EDUCATION FOR PATIENTS, DESIGNED BY PATIENTS: THE EXPERIENCE IN THE DESIGN OF A RHEUMATOID ARTHRITIS PRIMER

Rodriguez, F ; Realpe, L ; Castaño, Z ; Rodríguez-Vargas, G S ; Rojas-Villarraga, A ; Santos-Moreno, P

Annals of the rheumatic diseases, 2023, Vol.82 (Suppl 1), p.243-244 [Periódico revisado por pares]

London: BMJ Publishing Group LTD

Texto completo disponível

Citações Citado por
2
POS1384-HPR THE FUTURE OF PATIENT EDUCATION: DESIGN FOR A WEB PLATFORM FOR EDUCATION IN RHEUMATOID ARTHRITIS
POS1384-HPR THE FUTURE OF PATIENT EDUCATION: DESIGN FOR A WEB PLATFORM FOR EDUCATION IN RHEUMATOID ARTHRITIS
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

POS1384-HPR THE FUTURE OF PATIENT EDUCATION: DESIGN FOR A WEB PLATFORM FOR EDUCATION IN RHEUMATOID ARTHRITIS

Rodríguez-Vargas, G S ; Rodriguez, F ; Pinto-Florez, N ; Realpe, L ; Rojas-Villarraga, A ; Santos-Moreno, P

Annals of the rheumatic diseases, 2023, Vol.82 (Suppl 1), p.1045-1045 [Periódico revisado por pares]

London: BMJ Publishing Group LTD

Texto completo disponível

Citações Citado por
3
AB0548 EFFICACY AND SAFETY OF NIPOCALIMAB IN ADULT PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: DESIGN OF A PHASE 2 STUDY
AB0548 EFFICACY AND SAFETY OF NIPOCALIMAB IN ADULT PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: DESIGN OF A PHASE 2 STUDY
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

AB0548 EFFICACY AND SAFETY OF NIPOCALIMAB IN ADULT PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: DESIGN OF A PHASE 2 STUDY

Liu-Walsh, F ; Hartingsveldt, B V ; Zuraw, Q ; Hoffman, R W ; Rooney, T ; Gao, S ; Karpouzas, G ; Gordon, R ; Leu, J H ; Calderon, C ; Zazzetti, F ; Stevens, A M ; Vratsanos, G

Annals of the rheumatic diseases, 2023, Vol.82 (Suppl 1), p.1472-1473 [Periódico revisado por pares]

London: BMJ Publishing Group LTD

Texto completo disponível

Citações Citado por
4
POS0588-HPR DISCOVERING THE POTENTIAL OF DIGITAL BIOMARKERS IN THE WORK PROCESS OF THE RHEUMATOLOGY HEALTHCARE PROFESSIONALS, A DESIGN THINKING APPROACH. PRELIMINARY RESULTS OF THE HEALTHCARE PROFESSIONALS PERSPECTIVE
POS0588-HPR DISCOVERING THE POTENTIAL OF DIGITAL BIOMARKERS IN THE WORK PROCESS OF THE RHEUMATOLOGY HEALTHCARE PROFESSIONALS, A DESIGN THINKING APPROACH. PRELIMINARY RESULTS OF THE HEALTHCARE PROFESSIONALS PERSPECTIVE
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

POS0588-HPR DISCOVERING THE POTENTIAL OF DIGITAL BIOMARKERS IN THE WORK PROCESS OF THE RHEUMATOLOGY HEALTHCARE PROFESSIONALS, A DESIGN THINKING APPROACH. PRELIMINARY RESULTS OF THE HEALTHCARE PROFESSIONALS PERSPECTIVE

De Groot, P ; Luime, J ; Vis, M ; Kok, M R ; Tchetverikov, I

Annals of the rheumatic diseases, 2023, Vol.82 (Suppl 1), p.564-565 [Periódico revisado por pares]

London: BMJ Publishing Group LTD

Texto completo disponível

Citações Citado por
5
OP0093-PARE DISCOVERING THE POTENTIAL VALUES OF DIGITAL BIOMARKERS FOR INFLAMMATORY ARTHRITIS PATIENTS, A DESIGN THINKING APPROACH PRELIMINARY RESULTS OF THE PATIENTS’ PERSPECTIVE
OP0093-PARE DISCOVERING THE POTENTIAL VALUES OF DIGITAL BIOMARKERS FOR INFLAMMATORY ARTHRITIS PATIENTS, A DESIGN THINKING APPROACH PRELIMINARY RESULTS OF THE PATIENTS’ PERSPECTIVE
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

OP0093-PARE DISCOVERING THE POTENTIAL VALUES OF DIGITAL BIOMARKERS FOR INFLAMMATORY ARTHRITIS PATIENTS, A DESIGN THINKING APPROACH PRELIMINARY RESULTS OF THE PATIENTS’ PERSPECTIVE

De Groot, P ; Tchetverikov, I ; Goekoop-Ruiterman, Y ; Kok, M R ; Vis, M ; Olsder, W ; Foolen, J ; Bakker, R ; Luime, J

Annals of the rheumatic diseases, 2023, Vol.82 (Suppl 1), p.63-63 [Periódico revisado por pares]

London: BMJ Publishing Group LTD

Texto completo disponível

Citações Citado por
6
AB0877 TARGETING VASCULOPATHY TO SLOW FIBROSIS IN SYSTEMIC SCLEROSIS (SSC): DESIGN OF A PHASE II STUDY WITH A SOLUBLE GUANYLATE CYCLASE ACTIVATOR (SGCA)
AB0877 TARGETING VASCULOPATHY TO SLOW FIBROSIS IN SYSTEMIC SCLEROSIS (SSC): DESIGN OF A PHASE II STUDY WITH A SOLUBLE GUANYLATE CYCLASE ACTIVATOR (SGCA)
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

AB0877 TARGETING VASCULOPATHY TO SLOW FIBROSIS IN SYSTEMIC SCLEROSIS (SSC): DESIGN OF A PHASE II STUDY WITH A SOLUBLE GUANYLATE CYCLASE ACTIVATOR (SGCA)

Khanna, D ; Flack, M ; Litzenburger, T ; Fagan, N ; Distler, O

Annals of the rheumatic diseases, 2023, Vol.82 (Suppl 1), p.1653-1653 [Periódico revisado por pares]

London: BMJ Publishing Group LTD

Texto completo disponível

Citações Citado por
7
AB1481 EMERALD STUDY DESIGN: A TWO-COHORT, OPEN-LABEL, SINGLE-ARM STUDY OF EMAPALUMAB, AN ANTI–INTERFERON-Γ (IFNΓ) MONOCLONAL ANTIBODY, IN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) IN RHEUMATIC DISEASES
AB1481 EMERALD STUDY DESIGN: A TWO-COHORT, OPEN-LABEL, SINGLE-ARM STUDY OF EMAPALUMAB, AN ANTI–INTERFERON-Γ (IFNΓ) MONOCLONAL ANTIBODY, IN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) IN RHEUMATIC DISEASES
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

AB1481 EMERALD STUDY DESIGN: A TWO-COHORT, OPEN-LABEL, SINGLE-ARM STUDY OF EMAPALUMAB, AN ANTI–INTERFERON-Γ (IFNΓ) MONOCLONAL ANTIBODY, IN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) IN RHEUMATIC DISEASES

De Benedetti, F ; Krmar, R ; Kanceva, R ; Grom, A

Annals of the rheumatic diseases, 2023, Vol.82 (Suppl 1), p.1969-1970 [Periódico revisado por pares]

London: BMJ Publishing Group LTD

Texto completo disponível

Citações Citado por
8
AB0530 DESIGN OF 2 PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, GLOBAL TRIALS OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS
AB0530 DESIGN OF 2 PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, GLOBAL TRIALS OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

AB0530 DESIGN OF 2 PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, GLOBAL TRIALS OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS

Arriens, C ; Askanase, A ; Furie, R ; Morand, E F ; R Van Vollenhoven ; Connors, K ; Davey, M ; Delev, N ; Shah, V ; Stevens, A ; Wegman, T ; Hobar, C

Annals of the rheumatic diseases, 2023, Vol.82 (Suppl 1), p.1463-1463 [Periódico revisado por pares]

London: BMJ Publishing Group LTD

Texto completo disponível

Citações Citado por
9
AB1431 APPLICABILITY OF STANDARDIZED ULTRASOUND EXAMINATION TO ESTIMATE DISEASE ACTIVITY IN COMBINATION WITH JADAS AND INFLAMMATION MARKERS IN JIA PATIENTS – THE DAISY STUDY DESIGN
AB1431 APPLICABILITY OF STANDARDIZED ULTRASOUND EXAMINATION TO ESTIMATE DISEASE ACTIVITY IN COMBINATION WITH JADAS AND INFLAMMATION MARKERS IN JIA PATIENTS – THE DAISY STUDY DESIGN
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

AB1431 APPLICABILITY OF STANDARDIZED ULTRASOUND EXAMINATION TO ESTIMATE DISEASE ACTIVITY IN COMBINATION WITH JADAS AND INFLAMMATION MARKERS IN JIA PATIENTS – THE DAISY STUDY DESIGN

Lazarevic, D ; Malattia, C ; Rebollo Giménez, A I ; Rossi-Semerano, L ; Sözeri, B ; Tsinti, M ; Dermentzoglou, V ; Stefano, L ; Windschall, D ; Snipaitiene, A ; Carlini, L ; Scala, S ; Patrone, E ; Ruperto, N ; Vojinovic, J

Annals of the rheumatic diseases, 2023, Vol.82 (Suppl 1), p.1944-1945 [Periódico revisado por pares]

London: BMJ Publishing Group LTD

Texto completo disponível

Citações Citado por
10
AB1115 STUDY DESIGN AND FULL BASELINE SAMPLE CHARACTERISTICS OF PATIENTS FROM THE 24-MONTH MULTINATIONAL PROSPECTIVE PSORIATIC ARTHRITIS OBSERVATIONAL STUDY OF PERSISTENCE OF TREATMENT (PRO-SPIRIT)
AB1115 STUDY DESIGN AND FULL BASELINE SAMPLE CHARACTERISTICS OF PATIENTS FROM THE 24-MONTH MULTINATIONAL PROSPECTIVE PSORIATIC ARTHRITIS OBSERVATIONAL STUDY OF PERSISTENCE OF TREATMENT (PRO-SPIRIT)
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

AB1115 STUDY DESIGN AND FULL BASELINE SAMPLE CHARACTERISTICS OF PATIENTS FROM THE 24-MONTH MULTINATIONAL PROSPECTIVE PSORIATIC ARTHRITIS OBSERVATIONAL STUDY OF PERSISTENCE OF TREATMENT (PRO-SPIRIT)

Morel, J ; Lubrano, E ; Tillett, W ; Alten, R ; Kristensen, L E ; Chandran, V ; Treuer, T ; Burke, J ; Martínez-Ferrer, À ; Holzkaemper, T ; Gullick, N

Annals of the rheumatic diseases, 2023, Vol.82 (Suppl 1), p.1786-1787 [Periódico revisado por pares]

London: BMJ Publishing Group LTD

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Revistas revisadas por pares (180)

Data de Publicação 

De até
Refinar
  1. Antes de1995  (13)
  2. 1995Até2001  (15)
  3. 2002Até2011  (13)
  4. 2012Até2019  (18)
  5. Após 2019  (123)
  6. Mais opções open sub menu

Idioma 

  1. Inglês  (176)
  2. Russo  (5)
  3. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.